This site is intended for health professionals only

European Commission approves VELCADE®

Janssen-Cilag International NV (Janssen) has announced that the European Commission (EC) has approved the use of VELCADE® (bortezomib) as induction therapy (a first therapeutic option) in combination with dexamethasone (VD) or thalidomide and dexamethasone (VTD).[1] This licence extension will apply to adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with haematological stem cell transplantation.
Until now, VELCADE’s (bortezomib) indication has been limited to its use, in combination with melpha

Janssen-Cilag International NV (Janssen) has announced that the European Commission (EC) has approved the use of VELCADE® (bortezomib) as induction therapy (a first therapeutic option) in combination with dexamethasone (VD) or thalidomide and dexamethasone (VTD).[1] This licence extension will apply to adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with haematological stem cell transplantation.
Until now, VELCADE’s (bortezomib) indication has been limited to its use, in combination with melphalan and prednisone, in adult patients with multiple myeloma that are previously untreated and ineligible for stem cell transplant, and as a single agent in advanced multiple myeloma.[2] Multiple myeloma, a type of blood cancer, currently affects around 60,000 people in Europe.[3] This decision could mean significantly improved outcomes for many patients with this disease.
The approval by the EC was based on the analysis of data from two Phase III trials (IFM-2005-01, PETHEMA/GEM05) which demonstrated that treatment with VELCADE-based induction resulted in improvements in post-induction and post-transplant response rates and in progression-free survival (PFS); PFS and overall survival (OS) were secondary endpoints.
The trials studied the use of VELCADE-based regimens VD and VTD, compared to non-VELCADE-based regimens of vincristine plus doxorubicin and dexamethasone, or thalidomide and dexamethasone, respectively, as induction therapy prior to autologous stem cell transplant in adult patients with previously-untreated multiple myeloma.[4-5]
References
  1. European Commission: Velcade as a frontline induction therapy before stem cell transplantation. Available at:  http://ec.europa.eu/health/documents/community-register/html/h274.htm#EndOfPage Accessed August 2013.
  2. VELCADE EPAR Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000539/ human_med_001130.jsp&murl=menus/medicines/ medicines.jsp&mid=WC0b01ac058001d124. Accessed August 2013.
  3. Myeloma Patients Europe – FAQs. Available at http://www.myeloma-euronet.org/en/multiple-myeloma/faq.php. Accessed August 2013.
  4. Rosiñol L et al. Blood 2012; 120: 1589-1596.
  5. Harousseau J-L et al. J Clin Oncol 2010; 28:4630-4635.


Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: